GO:0034341 response to type II interferon: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034341 (response to type II interferon) describes any cellular or organismal change triggered by interferon-gamma (IFN-γ), the sole type II interferon.
• IFN-γ signaling proceeds through the JAK-STAT1 pathway, driving transcription of interferon-stimulated genes (ISGs) that coordinate antimicrobial, immunomodulatory and antiproliferative programs.
• The IFN-γ-related mRNA profile is a validated biomarker that predicts clinical response to PD-1 blockade immunotherapy in melanoma and other cancers.
• Type II interferon responses are central to neutrophil regulation of cancer immunotherapy and to host defense against intracellular pathogens [2,6].
• Dysregulated IFN-γ responses contribute to autoimmune conditions such as Sjögren's disease, where type II interferon-linked proteins serve as monitoring and treatment-response indicators.
• CRISPR knockout, knock-in, point-mutation and overexpression models enable causal dissection of IFN-γ response genes in immune and cancer biology [2,3,8].
Description
Response to type II interferon (GO:0034341) is the biological process by which a cell or organism alters its state or activity in response to interferon-gamma (IFN-γ), also known as type II interferon or immune interferon. Unlike type I interferons, which are produced by many cell types during viral infection, IFN-γ is primarily secreted by activated T cells and natural killer cells and acts as a key coordinator of cell-mediated immunity. The process encompasses changes in gene expression, enzyme production, secretion, movement and other cellular activities that collectively reprogram target cells for antimicrobial defense and immune regulation. Researchers study GO:0034341 because IFN-γ responses are mechanistically linked to cancer immunotherapy outcomes, host defense against intracellular pathogens, and autoimmune pathology [2,3,6,8]. The IFN-γ-related mRNA profile has been shown to predict clinical response to PD-1 blockade, making this pathway a translational biomarker. In parallel, neutrophil regulation of cancer immunotherapy is controlled by type II interferon, highlighting the breadth of this process across immune cell types. Because IFN-γ signaling intersects with macrophage polarization, ferroptosis regulation and viral hemorrhagic fever pathogenesis, GO:0034341 sits at the crossroads of immunology, oncology and infectious disease research [4,5,7]. Understanding its molecular components and regulatory logic is therefore essential for designing targeted experiments and interpreting immune phenotypes.
response to type II interferon At A Glance
| GO ID | GO:0034341 |
|---|---|
| GO term | response to type II interferon |
| Ontology | biological_process |
| Synonym | response to gamma-interferon; response to immune interferon; response to interferon-gamma; response to type II IFN |
| Major function | Mediates cellular and organismal changes triggered by IFN-γ, including JAK-STAT1-dependent gene expression, antimicrobial defense and immunomodulation |
| Key cytokine | Interferon-gamma (IFN-γ), also known as type II interferon |
| Primary signaling axis | JAK-STAT1 pathway leading to interferon-stimulated gene transcription |
| Cell types involved | T cells, natural killer cells, macrophages, neutrophils and many target cells [1,2,5] |
| Disease relevance | Cancer immunotherapy response, autoimmune disease, intracellular pathogen defense [2,3,6,8] |
What Is GO:0034341?
In our own words, GO:0034341 (response to type II interferon) is the collection of cellular and organismal processes that change in response to an interferon-gamma stimulus. It includes movement, secretion, enzyme production and gene expression changes that occur after a cell encounters IFN-γ, the cytokine also called type II interferon or immune interferon. This term captures the downstream consequences of IFN-γ receptor engagement rather than the receptor itself, and it is distinct from responses to type I interferons such as IFN-α and IFN-β.
Why Is response to type II interferon Important in Cell Biology?
GO:0034341 matters because IFN-γ is the principal cytokine of cell-mediated immunity, and the cellular response it triggers determines outcomes in cancer immunotherapy, infectious disease and autoimmunity [1,2,3,6,8]. The IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade, making this process directly actionable as a biomarker. Neutrophil regulation of cancer immunotherapy is controlled by type II interferon, revealing that GO:0034341 operates across innate and adaptive immune compartments. In autoimmune settings such as Sjögren's disease, proteins linked to type II interferon response serve as novel indicators for disease monitoring and for predicting treatment response to leflunomide and hydroxychloroquine combination therapy. Consequently, researchers in immunology, oncology and drug development routinely interrogate this process to understand mechanism and to stratify patients.
• Predicts clinical response to PD-1 blockade immunotherapy through IFN-γ-related mRNA profiles.
• Controls neutrophil regulation of cancer immunotherapy, linking innate immunity to treatment efficacy.
• Coordinates macrophage polarization programs studied in vitro for immunology research.
• Mediates host defense against intracellular pathogens including hemorrhagic fever viruses.
• Contributes to autoimmune pathology such as Sjögren's disease and serves as a treatment-response indicator.
• Interacts with ferroptosis biology, broadening its relevance to cancer cell death mechanisms.
• Is modulated by hormones such as testosterone during hepatic amebiasis, showing endocrine crosstalk.
• Provides a mechanistic framework for JAK-STAT1-targeted therapeutic strategies.
• Enables biomarker development for patient stratification in immuno-oncology.
• Supports comparative studies of type I versus type II interferon responses in disease models.
What Happens During response to type II interferon?
IFN-γ recognition and receptor engagement
In simple terms: A cell detects IFN-γ when the cytokine docks onto its surface receptor.
The response to type II interferon begins when IFN-γ binds its specific cell-surface receptor, a heterodimeric complex that activates associated Janus kinases. This engagement is the initiating event that distinguishes type II interferon responses from type I interferon responses, which use a different receptor complex. Receptor occupancy triggers trans-phosphorylation of JAK kinases and subsequent phosphorylation of the receptor cytoplasmic domain, creating docking sites for downstream signaling molecules.
JAK-STAT1 signal transduction
In simple terms: Signaling proteins inside the cell relay the message from the receptor to the nucleus.
Following receptor activation, STAT1 is recruited and phosphorylated by JAK kinases, then forms homodimers that translocate to the nucleus. This JAK-STAT1 axis is the canonical pathway for type II interferon signaling and is mechanistically distinct from the STAT1-STAT2-IRF9 complexes used by type I interferons. The phosphorylated STAT1 homodimers bind gamma-activated sequence (GAS) elements in the promoters of interferon-stimulated genes, initiating transcriptional reprogramming.
Interferon-stimulated gene transcription
In simple terms: The cell switches on a battery of defensive genes.
Nuclear STAT1 homodimers drive expression of interferon-stimulated genes that encode antimicrobial effectors, antigen-presentation machinery and immunomodulatory factors. The resulting IFN-γ-related mRNA profile has been characterized as a clinically relevant signature that predicts response to PD-1 blockade. This transcriptional output is the principal measurable consequence of GO:0034341 and is widely used as a readout in immunology research.
Cellular and organismal effector responses
In simple terms: The activated cell changes its behavior to fight infection or influence immunity.
Downstream of transcription, cells undergo changes in movement, secretion, enzyme production and other activities that define the response to type II interferon. In neutrophils, type II interferon controls regulation of cancer immunotherapy, demonstrating effector functions in innate immune cells. Macrophages polarize in response to IFN-γ, a process routinely modeled in vitro to study inflammatory phenotypes. These effector programs also intersect with ferroptosis regulation in cancer biology.
Integration with host defense and pathology
In simple terms: The response helps fight pathogens but can also contribute to disease.
Type II interferon responses are essential for defense against intracellular pathogens, and mice lacking type I or both type I and type II interferon responses are used to study hemorrhagic fever viruses. Hormonal factors such as testosterone can affect type I and type II interferon responses of neutrophils during hepatic amebiasis, showing context-dependent modulation. In autoimmune disease, proteins linked to type II interferon response serve as indicators for monitoring Sjögren's disease and predicting treatment response.
Key Genes Involved in GO:0034341 response to type II interferon
The following genes and proteins are central to the response to type II interferon (GO:0034341) and are commonly studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNG | Encodes interferon-gamma, the type II interferon cytokine | Ligand whose stimulus defines GO:0034341 |
| IFNGR1 | Type II interferon receptor subunit 1 | Receptor component required for IFN-γ recognition |
| IFNGR2 | Type II interferon receptor subunit 2 | Receptor component required for IFN-γ recognition |
| JAK1 | Janus kinase mediating IFN-γ receptor phosphorylation | Kinase essential for JAK-STAT1 signal transduction |
| JAK2 | Janus kinase mediating IFN-γ receptor phosphorylation | Kinase essential for JAK-STAT1 signal transduction |
| STAT1 | Transcription factor forming homodimers that bind GAS elements | Central mediator of type II interferon gene expression |
| IRF1 | Interferon regulatory factor induced by IFN-γ | Amplifies interferon-stimulated gene transcription |
| GBP1 | Guanylate-binding protein effector | Antimicrobial effector induced by IFN-γ |
| CXCL10 | Chemokine recruiting immune cells | IFN-γ-inducible chemokine used as response biomarker |
| IDO1 | Indoleamine 2,3-dioxygenase immunomodulatory enzyme | IFN-γ-inducible enzyme linked to immune regulation |
| CIITA | Major histocompatibility complex class II transactivator | IFN-γ-inducible regulator of antigen presentation |
| SOCS1 | Suppressor of cytokine signaling | Negative regulator of JAK-STAT1 signaling |
| PIAS1 | Protein inhibitor of activated STAT | Negative regulator of STAT1 activity |
| SLC7A11 | Cystine/glutamate transporter linked to ferroptosis | Connects IFN-γ response to ferroptosis biology |
| GPX4 | Glutathione peroxidase 4, ferroptosis regulator | Ferroptosis-related gene intersecting with immune response |
| FCGR3B | Neutrophil Fc receptor component | Relevant to neutrophil type II interferon regulation |
| HLA-DRA | MHC class II antigen presentation | IFN-γ-inducible antigen presentation gene |
How Is response to type II interferon Regulated?
The response to type II interferon is tightly regulated at multiple levels. SOCS1 and PIAS1 provide negative feedback that restrains JAK-STAT1 signaling, preventing excessive or prolonged inflammatory output. Receptor availability and JAK kinase activity set the threshold for pathway activation. Hormonal context can modulate the response, as testosterone affects type I and type II interferon responses of neutrophils during hepatic amebiasis. In disease settings, the magnitude of the IFN-γ-related mRNA profile reflects the integrated regulatory state and predicts clinical response to PD-1 blockade. Proteins linked to type II interferon response also serve as indicators for disease monitoring and treatment response in Sjögren's disease, illustrating that regulation is clinically observable.
response to type II interferon and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT1 | Cancer immunotherapy response and interferonopathies | STAT1 knockout and point-mutation cell lines [1,3] |
| IFNG | Immune regulation and pathogen defense | IFNG knockout mice and cell models |
| CXCL10 | Biomarker of PD-1 blockade response | CXCL10 reporter knock-in for expression tracking |
| SLC7A11 | Ferroptosis-related cancer biology | SLC7A11 knockout and overexpression models |
| FCGR3B | Neutrophil regulation of cancer immunotherapy | FCGR3B knockout neutrophil models |
Cancer immunotherapy response
The IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade, establishing GO:0034341 as a translational biomarker in immuno-oncology. Neutrophil regulation of cancer immunotherapy is controlled by type II interferon, showing that this process operates in innate immune cells that shape treatment outcomes. Ferroptosis, a form of regulated cell death, intersects with interferon biology and is being explored as a therapeutic vulnerability in cancer.
Autoimmune and inflammatory disease
Proteins linked to type II interferon response serve as novel indicators for disease monitoring and for predicting treatment response to leflunomide and hydroxychloroquine combination therapy in Sjögren's disease. Macrophage polarization, which is influenced by IFN-γ, is a key process in inflammatory pathology and is modeled in vitro for mechanistic studies.
Infectious disease and host defense
Mice lacking type I or both type I and type II interferon responses are used to study hemorrhagic fever viruses, revealing the importance of type II interferon in antiviral defense. Testosterone affects type I and type II interferon responses of neutrophils during hepatic amebiasis, demonstrating endocrine modulation of host defense. These models help dissect how GO:0034341 contributes to pathogen control or immunopathology.
From response to type II interferon-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for IFN-γ-induced transcription? | CRISPR knockout cell line with IFN-γ stimulation and RNA-seq [1,3] |
| Does a specific phosphorylation site control STAT1 activity? | Point-mutation knock-in of STAT1 phospho-site mutants |
| How does a tagged effector protein localize after IFN-γ treatment? | Tagged knock-in with imaging and proteomics |
| Does overexpression of an ISG enhance immunotherapy response? | Overexpression cell model in immune co-culture [2,3] |
| Which genes regulate neutrophil type II interferon responses? | CRISPR library screening in neutrophil-like cells |
| How do type I and type II interferon responses differ in antiviral defense? | Comparative knockout models of IFNAR and IFNGR |
How to Study the response to type II interferon Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes after IFN-γ stimulation | Identifying interferon-stimulated genes and biomarkers |
| Phospho-STAT1 immunoblot | JAK-STAT1 pathway activation | Validating signaling competence in knockout lines |
| Proteomics | Protein abundance and interactions in IFN-γ response | Mapping effector complexes and clinical markers |
| Imaging of tagged proteins | Subcellular localization and nuclear translocation | Visualizing STAT1 dynamics |
| Flow cytometry | Surface marker induction such as MHC class II | Single-cell phenotyping of IFN-γ responses |
| Macrophage polarization assay | Inflammatory phenotype acquisition | Testing gene function in innate immunity |
| Neutrophil functional assay | Type II interferon control of immunotherapy | Dissecting innate immune regulation |
| Pathogen challenge model | Host defense against intracellular pathogens | Evaluating type II interferon antiviral roles |
Transcriptomic profiling of IFN-γ responses
RNA-seq and targeted mRNA profiling are used to measure the IFN-γ-related mRNA signature that predicts clinical response to PD-1 blockade. These methods quantify interferon-stimulated gene expression and can be applied to knockout or overexpression models to identify causal genes. Comparative transcriptomics across cell types reveals the breadth of GO:0034341.
Proteomic and biochemical assays
Phospho-STAT1 immunoblotting and proteomic approaches measure JAK-STAT1 pathway activation after IFN-γ stimulation. These assays detect post-translational modifications and protein interactions that define the signaling cascade. Proteins linked to type II interferon response can also be quantified in clinical samples for disease monitoring.
Imaging and flow cytometry
Imaging of tagged STAT1 or effector proteins visualizes nuclear translocation and subcellular localization after IFN-γ treatment. Flow cytometry measures surface markers such as MHC class II that are induced by IFN-γ, providing a single-cell readout of GO:0034341. These methods are compatible with CRISPR-engineered reporter lines.
Functional immune assays
Macrophage polarization assays in vitro model IFN-γ-driven inflammatory phenotypes and are used to test gene function. Neutrophil functional assays assess type II interferon control of cancer immunotherapy responses. Antiviral and pathogen challenge models test the contribution of type II interferon to host defense.
How CRISPR Can Be Used to Study GO:0034341 response to type II interferon
Knockout
CRISPR knockout of genes such as STAT1, JAK1 or IFNGR1 ablates the response to type II interferon and is used to test whether a candidate gene is required for IFN-γ-induced transcription. Knockout models of interferon pathway components are also used to study hemorrhagic fever virus pathogenesis. Neutrophil knockout models help dissect type II interferon control of cancer immunotherapy.
Point Mutation
Point-mutation knock-in of phosphorylation sites or catalytic residues in STAT1 or JAK kinases allows precise dissection of signaling mechanisms without altering protein abundance. These models are valuable for distinguishing scaffolding functions from enzymatic activity in the IFN-γ response. Point mutants can also model disease-associated variants identified in interferonopathy patients.
Knock-in
Tagged knock-in of interferon-stimulated genes enables imaging and proteomic tracking of effector proteins after IFN-γ stimulation. Reporter knock-in of chemokines such as CXCL10 allows real-time monitoring of the IFN-γ-related mRNA profile in living cells. Knock-in models support studies of antigen presentation genes such as HLA-DRA.
Overexpression
Overexpression of interferon-stimulated genes or constitutively active STAT1 constructs amplifies the response to type II interferon and is used to test sufficiency in immune co-culture assays [2,3]. Overexpression models of ferroptosis regulators such as SLC7A11 and GPX4 connect IFN-γ biology to cell death pathways. These models complement knockout studies to establish causality.
How EDITGENE Supports response to type II interferon Research
Researchers studying response to type II interferon-related genes often need to determine whether a candidate gene is causally involved in IFN-γ signaling, whether a specific residue controls pathway output, or whether gene dosage alters immune phenotypes. EDITGENE provides publication-ready CRISPR cell models and screening services that enable these causal experiments in immune and cancer cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for response to type II interferon research.
Frequently Asked Questions About response to type II interferon
What is GO:0034341 response to type II interferon?
GO:0034341 is a Gene Ontology biological process term describing any change in a cell or organism resulting from an interferon-gamma stimulus, including changes in movement, secretion, enzyme production and gene expression.
What genes are involved in response to type II interferon?
Key genes include IFNG, IFNGR1, IFNGR2, JAK1, JAK2, STAT1, IRF1, GBP1, CXCL10, IDO1, CIITA, SOCS1 and PIAS1, which together mediate IFN-γ recognition, signaling and effector transcription.
How does IFN-γ signal inside the cell?
IFN-γ binds its receptor, activating JAK kinases that phosphorylate STAT1; STAT1 homodimers then translocate to the nucleus and bind GAS elements to induce interferon-stimulated genes.
Why is response to type II interferon important in cancer immunotherapy?
The IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade, and neutrophil regulation of cancer immunotherapy is controlled by type II interferon [2,3].
What is the difference between type I and type II interferon responses?
Type II interferon response is triggered by IFN-γ and uses JAK-STAT1 homodimers, whereas type I interferon responses are triggered by IFN-α/β and use distinct receptor and STAT complexes.
Which diseases are linked to type II interferon responses?
They are linked to cancer immunotherapy response, autoimmune diseases such as Sjögren's disease, and host defense against intracellular pathogens including hemorrhagic fever viruses [3,7,8].
How can I study response to type II interferon with CRISPR?
CRISPR knockout, point-mutation knock-in, tagged knock-in and overexpression models can test requirement, mechanism, localization and sufficiency of candidate genes in IFN-γ-stimulated cells [1,2,3].
What methods measure type II interferon pathway activation?
RNA-seq, phospho-STAT1 immunoblotting, proteomics, imaging of tagged proteins and flow cytometry for MHC class II induction are commonly used [1,3,8].
Is response to type II interferon involved in autoimmune disease?
Yes, proteins linked to type II interferon response serve as indicators for disease monitoring and predicting treatment response in Sjögren's disease.
What model systems are used to study type II interferon responses?
Cell lines with CRISPR edits, macrophage polarization cultures, neutrophil functional assays and mice lacking type I or both type I and type II interferon responses are used [2,5,7].
Conclusion
GO:0034341 (response to type II interferon) is a central biological process that converts IFN-γ stimulation into transcriptional and functional reprogramming through the JAK-STAT1 axis. Its clinical relevance spans cancer immunotherapy, autoimmune disease monitoring and antiviral host defense, as demonstrated by the predictive value of IFN-γ-related mRNA profiles and by type II interferon-linked biomarkers in Sjögren's disease [3,8]. CRISPR-based knockout, knock-in, point-mutation and overexpression models provide the causal toolkit needed to dissect this pathway gene by gene [1,2,3].
References
- 1. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling.. Nat Rev Immunol 5(5):375-86 PMID: 15864272
- 2. Pei S et al.. 2026. Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon.. Immunity 59(7):1982-1998.e6 PMID: 42296966
- 3. Ayers M et al.. 2017. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.. J Clin Invest 127(8):2930-2940 PMID: 28650338
- 4. Chen X et al.. 2021. Broadening horizons: the role of ferroptosis in cancer.. Nat Rev Clin Oncol 18(5):280-296 PMID: 33514910
- 5. Huang X et al.. 2018. Polarizing Macrophages In Vitro.. Methods Mol Biol 1784:119-126 PMID: 29761394
- 6. Er-Lukowiak M et al.. 2023. Testosterone affects type I/type II interferon response of neutrophils during hepatic amebiasis.. Front Immunol 14:1279245 PMID: 38179044
- 7. Clarke EC et al.. 2020. The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 1: Potential effects on adaptive immunity and response to vaccination.. Antiviral Res 174:104703 PMID: 31932041
- 8. Wong WY et al.. 2025. Proteins linked to type II interferon response in Sjögren's disease: novel indicators for disease monitoring and predicting treatment response to leflunomide and hydroxychloroquine combination therapy.. Front Immunol 16:1566377 PMID: 41181128
